G6PC3: Difference between revisions
CSV import |
CSV import |
||
| Line 35: | Line 35: | ||
[[Category:Growth factors]] | [[Category:Growth factors]] | ||
{{No image}} | {{No image}} | ||
__NOINDEX__ | |||
Latest revision as of 12:28, 17 March 2025
Granulocyte Colony-Stimulating Factor (G-CSF) is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream. It is a cytokine and hormone that plays a critical role in hematopoiesis, the process of blood cell production.
Structure and Function[edit]
G-CSF is a 174-amino acid protein with a molecular weight of approximately 19.6 kDa. It is produced by various tissues, including the endothelium, macrophages, and a number of other immune cells. The primary function of G-CSF is to regulate the production and release of neutrophils from the bone marrow.
Mechanism of Action[edit]
G-CSF binds to the G-CSF receptor (G-CSFR) on the surface of hematopoietic stem cells and progenitor cells in the bone marrow. This binding activates intracellular signaling pathways, including the JAK/STAT, PI3K/AKT, and MAPK pathways, leading to the proliferation, differentiation, and survival of neutrophil precursors.
Clinical Applications[edit]
G-CSF is used clinically to treat neutropenia, a condition characterized by an abnormally low number of neutrophils. It is particularly useful in patients undergoing chemotherapy, which often results in neutropenia. G-CSF reduces the risk of infection in these patients by increasing neutrophil counts.
Recombinant Forms[edit]
Recombinant forms of G-CSF, such as filgrastim and pegfilgrastim, are widely used in clinical practice. Filgrastim is a non-glycosylated form of G-CSF produced in Escherichia coli, while pegfilgrastim is a pegylated form that has a longer half-life, allowing for less frequent dosing.
Side Effects[edit]
Common side effects of G-CSF administration include bone pain, headache, and fatigue. More serious side effects can include splenic rupture and acute respiratory distress syndrome (ARDS), although these are rare.
Research and Development[edit]
Ongoing research is exploring the use of G-CSF in other conditions, such as myocardial infarction and stroke, due to its potential to mobilize stem cells and promote tissue repair.
Also see[edit]
| Cell signaling: cytokines | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|